[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Arbor Research Collaborative for Health\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":133},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,70,93,109],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100436960","pancreatic-cancer-early-detection-consortium-100436960",false,"NCT04970056","Pancreatic Cancer Early Detection Consortium","PRECEDE","Inclusion Criteria:\n\nIndividuals from the following groups who present for clinical evaluation and assessment of PDAC risk at any of the participating sites can be offered participation in the PRECEDE database:\n\nCohort 1\n\nIndividuals without history of PDAC meeting any of the following criteria:\n\n1. 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤10 years younger than earliest PDAC in family at time of diagnosis.\n2. 2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family\n3. BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family\n4. Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+\n5. Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+\n6. Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age 40+\n\nCohort 2\n\nIndividuals without history of PDAC meeting any of the following criteria:\n\n1. ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history, age 50+\n2. 2+ relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age 50+ or 10 years younger than earliest PDAC in family\n3. 1 first degree relative with PDAC ≤ age 45; age up to 10 years younger than PDAC diagnosis in family member\n\nCohort 3 Individual meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e. too young to qualify for Cohorts 1 or 2)\n\nCohort 4 Individuals without history of PDAC presenting for evaluation who do not meet any criteria for 1-3, 6, or the Cyst Cohort.\n\nCohort 5 Individuals without history of PDAC who are not otherwise engaged in pancreas surveillance at a participating site may be invited to participate in the PRECEDE database and to donate a biosample (e.g. blood, saliva, and\u002For buccal swab) for discovery studies. This may include relatives of individuals in Cohorts 1-4,6, and the Cyst Cohort.\n\nCohort 6a\n\nIndividuals diagnosed with PDAC or pancreatic high-grade dysplasia after enrollment in PRECEDE meeting any of the following criteria:\n\n1. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other\n2. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11\n\nCohort 6b\n\nIndividuals with a personal history of PDAC or pancreatic high-grade dysplasia meeting any of the following criteria:\n\n1. Family history includes at least one first degree relative with PDAC, or 2 relatives with PDAC who are first degree related to each other\n2. Personal or family history of a pathogenic or likely pathogenic germline variant in ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2,PMS2, PRSS1, STK11\n3. Diagnosed ≤ age 45\n\nCohort 6c Individuals with newly diagnosed early stage (stage I or stage II) PDAC seen at a PRECEDE site that do not meet the criteria for 6a or 6b.\n\nCohort 6d Individuals with PDAC seen at a PRECEDE site that do not meet the criteria for 6a, 6b, or 6c.\n\nCyst Cohort Individuals with a personal history of a pancreatic cystic neoplasm not meeting any criteria for Cohorts 1-3 or 6 (no known family history of PDAC, no known pathogenic germline variants linked to PDAC risk)\n\nExclusion Criteria:\n\n* Individuals not meeting the criteria above.",true,"ALL","18 Years","90 Years",{"count":21,"type":22},20000,"ESTIMATED","OBSERVATIONAL","The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and\u002For individuals carrying pathogenic\u002Flikely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.",[26,27,28,29],"Pancreas Cancer","Pancreas Cyst","Pancreatic Ductal Adenocarcinoma","Genetic Predisposition","RECRUITING","2026-06-23",{"date":33,"type":34},"2026-06-26","ACTUAL",{"date":36,"type":34},"2020-09-18",{"date":38,"type":22},"2030-12-31",{"name":40,"class":41},"Arbor Research Collaborative for Health","OTHER",60,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100376409","primary-sclerosing-cholangitis-in-children-100376409","NCT04181138","Primary Sclerosing Cholangitis in Children","Prospective Observational Study of Primary Sclerosing Cholangitis (PSC) in Children","Inclusion Criteria:\n\nPatients with the clinical diagnosis of large or small duct PSC made at any time prior to enrollment are screened for eligibility to participate in this prospective cohort study. The site PI will determine eligibility following review of MRCP or ERCP images with the site radiologist to confirm presence of an abnormal cholangiogram at the time of diagnosis of large duct PSC. Liver histopathology obtained at the time of diagnosis of small duct PSC will be reviewed with the site pathologist prior to enrollment.\n\nIndividuals must meet all of the Inclusion criteria in order to be eligible to participate in the study:\n\n1. Aged 2 through 25 years at time of screening.\n2. Diagnosis of large duct PSC based on review of cholangiogram by MRC, ERC, or intraoperative cholangiogram (IOC) by the site radiologist and interpreted to be consistent with PSC, based on one or more of the following:\n\n   * Focal structuring of the bile duct(s)\n   * Dominant stricture of the common bile duct\n   * Saccular dilatation of bile duct(s)\n   * Beaded appearance of bile duct(s)\n   * Pruning appearance of the distal bile duct branches\n\n   AND\u002FOR\n3. Diagnosis of small duct PSC based on review of liver histopathology by the site pathologist and interpreted to be compatible with PSC:\n\n   * Probable small duct PSC: biopsy with ≥3 of 5 criteria: periductal edema, concentric inflammation, bile duct injury, ductular reaction, and neutrophils in bile ducts (cholangitis) OR...\n   * Definitive small duct PSC: Periductal fibrosis\u002F \"onion skinning\" around interlobular bile ducts or smaller profiles\n4. Stated willingness to comply with all study procedures and availability for the duration of the study.\n5. Able to provide informed consent\u002Fassent\n\nParticipants for the imaging study are eligible if they are:\n\n1. Aged 8 through 25 years at the time of screening\n2. No absolute contraindication to MRI\n3. No skin condition that could be aggravated by MREL\n4. Meet all other eligibility criteria of the PSC Observational Study\n5. For whom none of the exclusion criteria apply\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria at baseline will be excluded from participation in this study.\n\n1. History of liver transplantation\n2. History bone marrow transplantation\n3. History of primary or acquired immunodeficiency predisposing to secondary sclerosing cholangitis, for instance: hyper-IgM syndrome, severe combined immunodeficiency (SCID) syndrome, common variable immunodeficiency (CVID) syndrome, cartilage hair hypoplasia syndrome, or HIV\u002FAIDS\n4. History of histiocytosis, including Langerhans cell histiocytosis (LCH), or hemophagocytic lymphohistiocytosis (HLH)\n5. History of ischemic cholangitis\n6. History of portal vein thrombosis with biliopathy, veno-occlusive disease, or abdominal radiation vasculopathy\n7. History of recurrent pyogenic cholangitis\n8. History of biliary tract surgery for cholecystolithiasis prior to cholangiogram\u002Fliver biopsy evaluated to determine enrollment\n9. History of biliary tract surgery for choledochal cyst\n10. History of hepatocellular carcinoma, or hepatoblastoma\n11. History of surgical biliary trauma\n12. History of congenital cytomegalovirus (CMV) hepatitis\n13. History of Sickle Cell Disease\n14. History of cystic fibrosis, biliary atresia, Caroli disease\u002Fcongenital hepatic fibrosis, or progressive familial intrahepatic cholestasis type 3\u002FMDR3 disease\n15. History of cardiac hepatopathy.\n16. History of metabolic disorders, including Wilson's disease, glycogen storage disorder, Alpha-1 Antitrypsin deficiency\n17. Diagnosis of systemic lupus erythematosus (SLE)\n18. Concurrent pregnancy at the time of enrollment -","2 Years","25 Years",{"count":53,"type":22},1000,"Primary sclerosing cholangitis (PSC) is a rare liver disease that damages the liver's bile ducts. Bile ducts are tiny tubes that carry bile from the liver to the small intestine. Bile is a liquid produced by the liver that helps us absorb and use the nutrients in the food we eat. In people with PSC, the bile backs up into the liver and will damage it, causing scarring of the liver.\n\nThe purposes of this study are to:\n\n* Collect medical and other data to learn more about PSC, how it progresses, and identify factors that may cause the disease to progress more quickly.\n* Ask questions about how PSC symptoms affect your child's life to learn more about its impact on your child's daily functioning\n* Children with PSC who are seen at one of the participating clinical sites in the Childhood Liver Disease Research Network (ChiLDReN) will be asked to contribute information, DNA, and other specimens. The information and specimens will be available to investigators to carry out approved research aimed at learning more about the possible causes and long-term effects of PSC.",[56,57,58],"Primary Sclerosing Cholangitis","Liver Diseases","Cholangitis, Sclerosing",[60,56],"Pediatric Liver Disease","2026-06-03",{"date":63,"type":34},"2026-06-04",{"date":65,"type":34},"2021-12-30",{"date":67,"type":22},"2029-05-31",{"name":40,"class":41},12,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":91,"locationsCount":92},"100083583","biliary-atresia-study-in-infants-and-children-100083583","NCT00345553","Biliary Atresia Study in Infants and Children","Biliary Atresia Study in Infants and Children (BASIC)","BASIC","Inclusion Criteria:\n\n1. Participants need to have a confirmed diagnosis of BA determined by chart review including review of pertinent diagnostic biopsy reports, radiologic reports and surgical reports (if surgery was performed).\n2. Participants need to be \\>6 months of age up to and equal to the age of 20 (participants enrolled at 20 years of age will have one visit).\n3. Participants with their native liver.\n4. Parent, guardian or participant (if 18 years of age or older) is willing to provide informed consent and, when appropriate, the participant is willing to assent.\n\nExclusion Criteria:\n\n1. Currently participating in the ChiLDReN study PROBE.\n2. Inability to confirm original diagnostic evaluation of biliary atresia.\n3. Inability or unwillingness of family or participant to participate in all scheduled visits.\n4. History of liver transplantation.","6 Months","20 Years",{"count":81,"type":22},1265,"Little is known about the factors that cause biliary atresia nor the factors that influence disease progression. The purpose of this study is to collect the pertinent clinical information, genetic material and body fluid samples to enable investigators to address the following aims: To identify the gene or genes implicated in the etiology of BA; To characterize the natural history of the older, non-transplanted child with BA.",[84],"Biliary Atresia",[84,86],"Cholestasis",{"date":63,"type":34},{"date":89,"type":34},"2006-05-16",{"date":67,"type":22},{"name":40,"class":41},16,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":78,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":104,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":108,"locationsCount":92},"100062542","a-prospective-database-of-infants-with-cholestasis-100062542","NCT00061828","A Prospective Database of Infants With Cholestasis","Childhood Liver Disease Research Network (ChiLDReN): A Prospective Database of Infants With Cholestasis","PROBE","INCLUSION CRITERIA\n\n* Infant's age less than or equal to 180 days at initial presentation at the ChiLDReN clinical site.\n* Diagnosis of cholestasis defined by serum direct or conjugated bilirubin greater than or equal to 2 mg\u002Fdl and suspected biliary atresia.\n* The subject's parent(s)\u002Fguardian(s) willing to provide informed written consent.\n\nEXCLUSION CRITERIA\n\n* Acute liver failure.\n* Previous hepatobiliary surgery with dissection or excision of biliary tissue.\n* Diagnoses of bacterial or fungal sepsis (except where associated with metabolic liver disease)\n* Diagnoses of hypoxia, shock or ischemic hepatopathy within the past two weeks (If the cholestasis persists beyond two weeks of the initiating event, the infant can be enrolled).\n* Diagnosis of any malignancy.\n* Presence of any primary hemolytic disease (except when diagnosed with biliary atresia or another cholestatic disease being studied by ChiLDREN).\n* Diagnosis of any drug or Total parenteral nutrition (TPN)-associated cholestasis (except when diagnosed with biliary atresia or another cholestatic disease being studied by ChiLDREN).\n* Diagnosis with Extracorporeal membrane oxygenation (ECMO)-associated cholestasis.\n* Birth weight less than 1500g (except when diagnosed with biliary atresia).",{"count":53,"type":22},"Biliary atresia, idiopathic neonatal hepatitis, and specific genetic cholestatic conditions are the most common causes of jaundice and hyperbilirubinemia that continue beyond the newborn period. The long term goal of the Childhood Liver Disease Research Network (ChiLDReN) is to establish a database of clinical information and plasma, serum, and tissue samples from cholestatic children to facilitate research and to perform clinical, epidemiological and therapeutic trials in these important pediatric liver diseases.",[84],{"date":63,"type":34},{"date":106,"type":34},"2004-04-21",{"date":67,"type":22},{"name":40,"class":41},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":117,"conditions":118,"keywords":121,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":132},"100636110","comparisons-of-biochemical-and-clinical-outcomes-of-hemodialysis-patients-treated-with-middle-cut-off-dialyzers-versus-high-flux-hemodialysis-or-hemodiafiltration-100636110","NCT07561424","Comparisons Of Biochemical And Clinical Outcomes Of Hemodialysis Patients Treated With Middle Cut-Off Dialyzers Versus High-Flux Hemodialysis Or Hemodiafiltration","CONCORDIA","Inclusion Criteria\n\n* 18 years of age or older\n* Treated at an in-centre dialysis clinic\n* Receiving chronic, maintenance HD",{"count":53,"type":22},"The CONCORDIA study is a retrospective, observational study evaluating clinical and biochemical outcomes among patients receiving maintenance hemodialysis with medium cut-off (MCO) dialyzers (Theranova) compared with high-flux hemodialysis (HF-HD) and hemodiafiltration (HDF). Using real-world data from non-DOPPS Theranova sites and the DOPPS cohort as an external control, the study aims to assess whether MCO dialyzers are associated with improved outcomes versus HF-HD and non-inferior outcomes compared with HDF. The primary outcome is all-cause mortality, with secondary outcomes including cardiovascular events, hospitalizations, infections, and laboratory measures related to anemia, mineral metabolism, and inflammation.",[119,120],"ESKD","Dialysis Patients",[122,123],"dialysis","HDF","2026-04-28",{"date":126,"type":34},"2026-05-01",{"date":128,"type":34},"2026-02-01",{"date":130,"type":22},"2026-09-01",{"name":40,"class":41},1,""]